.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,602,133

« Back to Dashboard

Summary for Patent: 5,602,133

Title: Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
Abstract:Novel methods of using thiazolidinone derivatives and related antihyperglycemic agents to treat populations at risk for developing noninsulin-dependent diabetes mellitus (NIDDM) and complications arising therefrom are disclosed. In one embodiment, the compounds of the invention are used to treat polycystic ovary syndrome in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus. In another embodiment, the compounds of the invention are used to treat gestational diabetes in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus.
Inventor(s): Antonucci; Tammy (Meguon, WI), Lockwood; Dean (Ann Arbor, MI), Norris; Rebecca (Kewadin, MI)
Assignee: Warner-Lambert Company (Morris Plains, NJ)
Application Number:08/469,398
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form; Compound;
Patent PDF download available with subscription

No matches for this query

Premature patent expiration for: 5,602,133

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
5,602,133 February 11, 2009

International Patent Family for Patent: 5,602,133

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria198045<disabled in preview>
Austria303147<disabled in preview>
Austria376829<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc